Physician profile
Robert E Botti
NPI 1841285376
$12,270.97
in general payments reported to CMS, 2019-2025
37 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,545 · 2020: $1,770 · 2021: $2,193 · 2022: $1,771 · 2023: $1,184 · 2024: $1,586 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,497.62 | 2019-2025 | |
| Boston Scientific Corporation | $2,400.01 | 2019-2025 | Watchman Flx, Farapulse, Versacross Access Solution |
| Astrazeneca Pharmaceuticals Lp | $972.90 | 2019-2024 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $842.39 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $693.04 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $658.34 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $551.03 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $450.82 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $436.56 | 2019-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $435.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.20 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $311.59 | 2019-2022 | |
| Abbott Laboratories | $284.55 | 2019-2021 | |
| Esperion Therapeutics, INC. | $211.54 | 2020-2024 | Nexletol |
| Medtronic, INC. | $206.10 | 2021-2023 | Micra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $135.69 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $107.36 | 2025 | Uptravi, Opsumit |
| Biotronik INC. | $103.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $85.48 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $58.49 | 2021 | |
| Alnylam Pharmaceuticals INC. | $57.76 | 2021-2025 | Onpattro |
| Scpharmaceuticals INC. | $53.78 | 2023-2025 | |
| Novo Nordisk INC | $51.21 | 2019-2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $45.46 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $35.24 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $30.56 | 2021 | |
| Elutia, INC. | $25.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.79 | 2021 | |
| G Medical Diagnostic Services, INC. | $21.56 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.47 | 2024 | |
| Philips North America LLC | $17.20 | 2022 | |
| Preventice Services, LLC | $15.86 | 2021 | |
| Genzyme Corporation | $15.49 | 2023 | |
| Portola Pharmaceuticals, LLC | $15.33 | 2019 | |
| Cvrx, INC. | $15.17 | 2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2024 | |
| Terumo Medical Corporation | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Botti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.